EBS vs RUN · rev $1.04B vs P/E 6.0, rev $2.04B
Emergent Biosolutions Inc (EBS) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
EBS currently screens at market cap $416.4M. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the EBS and RUN stock pages for the full models.
Not investment advice.